Cargando…

A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

SIMPLE SUMMARY: There are limited treatments for patients with HER2-negative breast cancer, especially for patients with metastatic breast cancer. This study aimed to observe the efficacy and safety of low-dose apatinib combined with chemotherapy in real-world clinical diagnosis and treatment of HER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Tianyu, Sun, Chunxiao, Liang, Yan, Yang, Fan, Yan, Xueqi, Bao, Shengnan, Zhang, Yucheng, Huang, Xiang, Fu, Ziyi, Li, Wei, Yin, Yongmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454649/ https://www.ncbi.nlm.nih.gov/pubmed/36077621 http://dx.doi.org/10.3390/cancers14174084

Ejemplares similares

A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression
por: Yan, Xueqi, et al.
Publicado: (2022)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Tan, Aihua, et al.
Publicado: (2023)

High rate of epidermal growth factor receptor-mutated primary lung cancer in patients with primary breast cancer
por: Zeng, Tianyu, et al.
Publicado: (2022)

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study
por: Gou, Miaomiao, et al.
Publicado: (2018)

Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials
por: Bao, Shengnan, et al.
Publicado: (2021)

Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment
por: Liu, Zhaoyun, et al.
Publicado: (2021)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
por: Zhao, Lingying, et al.
Publicado: (2022)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
por: Bao, Shengnan, et al.
Publicado: (2021)

Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer
por: Hu, Xichun, et al.
Publicado: (2014)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2022)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
por: Yuan, Yang, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
por: Zhang, Ruyan, et al.
Publicado: (2023)

Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis
por: Yan, Xueqi, et al.
Publicado: (2021)

A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer
por: Gamucci, Teresa, et al.
Publicado: (2016)

Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting
por: Leng, Jiao, et al.
Publicado: (2019)

Apatinib treatment is effective for metastatic malignant phyllodes tumors of the breast: a case report
por: Wang, Xiaolu, et al.
Publicado: (2021)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Application of apatinib after multifaceted therapies for metastatic breast cancer
por: Wang, Jue, et al.
Publicado: (2020)

Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study
por: Zhang, Jindi, et al.
Publicado: (2019)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
por: Zhang, Qingyuan, et al.
Publicado: (2022)

Response to lower dose TNF inhibitors in axial spondyloarthritis; a real-world multicentre observational study
por: Van Rossen, Liz, et al.
Publicado: (2020)

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023)

Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study
por: Su, Yung-Yeh, et al.
Publicado: (2022)

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China
por: Peng, Wanren, et al.
Publicado: (2020)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC)
por: Shi, Liang, et al.
Publicado: (2022)

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices
por: Tan, Ruoding, et al.
Publicado: (2022)

Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
por: Li, Ting, et al.
Publicado: (2019)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report
por: Liang, Li-Jun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7m1q4nfk073haifdvgemm0e5sh